FILE PHOTO: The logo of Swiss pharmaceutical group Lonza is seen at its headquarters in Basel, Switzerland March 2, 2020. REUTERS/Arnd Wiegmann/File Photo
| Photo Credit:
ARND WIEGMANN
A delegation from the company met Minister for Industries D Sridhar Babu and CEO of Telangana Lifesciences Shakthi M Nagappan and formally conveyed the decision on the new GCC.
Headquartered in Switzerland and founded in 1897, Lonza operates across more than 30 sites worldwide and employs close to 20,000 professionals. In 2025, the company reported sales of CHF 6.5 billion and a Core EBITDA of CHF 2.1 billion.
The decision follows an extensive evaluation process from which Hyderabad was identified as a preferred destination based on its strong talent pool, quality infrastructure and supportive industrial ecosystem.
“Lonza’s investment further strengthens Telangana’s position as a preferred destination for innovation-led growth in the global biopharmaceutical industry. I am delighted that the centre has the potential to create a substantial number of new jobs over the years. We remain committed to supporting such endeavours that promise job creation for our citizens,’’ Sridhar Babu said in a release.
Shakthi M Nagappan, CEO, Telangana Lifesciences, said, “This decision marks another significant milestone in the continued expansion of Telangana’s life sciences ecosystem. We look forward to working closely with Lonza to ensure the successful execution of this project and to enable long-term value creation.’’
The new GCC is expected to contribute to the generation of high-value employment and further integrate Hyderabad into the global biopharmaceutical value chain, he added.
Published on March 5, 2026